valproic acid has been researched along with furosemide in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 14 (36.84) | 29.6817 |
| 2010's | 16 (42.11) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Cha, SH; Endou, H; Fukushima , JI; Goya, T; Kanai, Y; Kobayashi, Y; Sekine, T | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chatzopoulou, M; Demopoulos, VJ; Kristl, A; Patsilinakos, A; Prnova, MS; Ragno, R; Stefek, M; Tsantili-Kakoulidou, A; Vallianatou, T; Zakelj, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Baiula, M; Bolognesi, ML; Kobrlova, T; Mercolini, L; Monti, B; Petralla, S; Protti, M; Rossi, M; Soukup, O; Spampinato, SM | 1 |
| Richens, A | 1 |
| Chilovi, F; Dobrilla, G; Felder, M | 1 |
| Gorchein, A | 1 |
| Duwe, K; Kuhnz, W; Nau, H; Wittfoht, W | 1 |
| Maruyama, T; Otagiri, M; Shinozawa, S; Suenaga, A; Takamura, N | 1 |
| Matsuo, H; Nakano, H; Ohtani, H; Sawada, Y; Takanaga, H; Tsukimori, K; Ushigome, F | 1 |
| Borowicz, KK; Czuczwar, SJ; Kozinska, J; Luszczki, JJ; Sawicka, KM | 1 |
| Darcissac, C; de La Gastine, B; Gabriel, L; Goutelle, S; Sève, P; Vial, T | 1 |
| Gupta, R; Jha, A; Patel, H; Patel, N; Singh, K; Soni, K; Srinivas, NR | 1 |
| Abdolmaleki, Z; Faedmaleki, F; Samadianzakaria, A | 1 |
5 review(s) available for valproic acid and furosemide
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interactions with antiepileptic drugs.
Topics: Acetaminophen; Acetazolamide; Anti-Anxiety Agents; Anticoagulants; Anticonvulsants; Carbamazepine; Diazepam; Drug Interactions; Furosemide; Gonadal Steroid Hormones; Griseofulvin; Humans; Phenobarbital; Phenytoin; Primidone; Thiazines; Urea; Valproic Acid; Vitamin D | 1977 |
[Lower limb edema during valpromide treatment: case report and literature review].
Topics: Aged, 80 and over; Anticonvulsants; Edema; Female; Furosemide; Humans; Lower Extremity; Valproic Acid; Withholding Treatment | 2015 |
33 other study(ies) available for valproic acid and furosemide
| Article | Year |
|---|---|
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
Topics: Amino Acid Sequence; Animals; Carrier Proteins; Chromosome Mapping; Chromosomes, Human, Pair 11; Cloning, Molecular; Gene Library; Humans; Kidney Tubules, Proximal; Molecular Sequence Data; Oocytes; Organic Anion Transporters, Sodium-Independent; Sequence Homology, Amino Acid; Tissue Distribution; Transfection; Xenopus laevis | 2001 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.
Topics: Aldehyde Reductase; Animals; Cell Membrane Permeability; Dose-Response Relationship, Drug; Enzyme Inhibitors; Jejunum; Lenses; Male; Models, Molecular; Molecular Structure; Phenols; Pyrroles; Rats; Rats, Wistar; Sorbitol; Structure-Activity Relationship | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
Topics: | 2020 |
[Acute drug-induced pancreatitis].
Topics: Acute Disease; Asparaginase; Azathioprine; Chlorothiazide; Drug-Related Side Effects and Adverse Reactions; Estrogens; Furosemide; Humans; Pancreatitis; Sulfonamides; Tetracycline; Valproic Acid | 1985 |
Drug safety in porphyria.
Topics: Animals; Disease Models, Animal; Furosemide; Humans; Porphyrias; Rats; Rifampin; Risk; Valproic Acid | 1980 |
Microscale ultrafiltration technique for determining free drug in 50-microL serum samples.
Topics: Animals; Chloramphenicol; Diazepam; Furosemide; Humans; Indomethacin; Infant; Infant, Newborn; Microchemistry; Pharmaceutical Preparations; Phenobarbital; Phenytoin; Ultrafiltration; Valproic Acid | 1984 |
Effects of fatty acids on serum binding between furosemide and valproic acid.
Topics: Anticonvulsants; Diuretics; Drug Interactions; Fatty Acids; Furosemide; Humans; Valproic Acid | 1998 |
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
Topics: 3-O-Methylglucose; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Alanine; Anticonvulsants; Biological Transport; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cell Polarity; Choriocarcinoma; Epithelial Cells; Fatty Acids; Female; Furosemide; Humans; Hydrogen-Ion Concentration; Kinetics; p-Aminohippuric Acid; Placenta; Placental Circulation; Pregnancy; Salicylic Acid; Sodium Azide; Temperature; Teratogens; Tumor Cells, Cultured; Uncoupling Agents; Uterine Neoplasms; Valproic Acid | 2001 |
Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model.
Topics: Analysis of Variance; Animals; Anticonvulsants; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Electroshock; Furosemide; Male; Mice; Seizures; Valproic Acid | 2007 |
A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard.
Topics: Calibration; Chromatography, Liquid; Edetic Acid; Furosemide; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Valproic Acid | 2016 |
The effect of valproic acid and furosemide on the regulation of the inflammasome complex (NLRP1 and NLRP3 mRNA) in the brain of epileptic animal model.
Topics: Animals; Brain; Disease Models, Animal; DNA-Binding Proteins; Epilepsy; Furosemide; Inflammasomes; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Wistar; RNA, Messenger; Valproic Acid | 2022 |